1 min read
Merck Ends Nemtabrutinib Development After Phase 3 Trial Review
A data monitoring committee raised concerns that the drug’s potential benefits might not outweigh its risks.

During a Phase 3 trial review, a data monitoring committee raised concerns that nemtabrutinib’s potential benefits did not offset its risks; Merck & Co. has ended development of the drug.
Nemtabrutinib is an oral, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).